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A B ST R AC T  
 
Aim: Multiple sclerosis (MS), which is inflammatory in its pathogenesis, damages the myelin sheath in the 
central nervous system (CNS) and causes axonal loss. Epicardial fat tissue (EFT), located between the 
myocardium and the visceral layer of the pericardium, surrounds the heart and several inflammatory cytokines 
is secreted from this tissue. In this study, we aimed to investigate EFT thickness in MS patients and compared 
with that of volunteer non-MS subjects. 
Methods: A total of 154 subjects comprising 61 MS patients and 93 volunteers matched for gender and age 
were included in our study.  Epicardial fat tissue thickness was measured by echocardiography. All values 
were compared between groups. 
Results: Echocardiographic parameters were similar in both groups. However, the mean EFT thickness was 
significantly higher in the MS group than in the control group (p<0.001). Epicardial fat tissue thickness was 
also significantly correlated with the presence of MS (r=0.33, p<0.001). 
Conclusion: The results of our study suggest that the increase in epicardial adipose tissue thickness in MS 
patients may be a predictive factor for cardiovascular disease. However, the clinical significance of this finding 
and its relevance to MS pathogenesis should be investigated in further studies. 
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Introduction 
Multiple sclerosis (MS), which is inflammatory 
in its pathogenesis, damages the myelin sheath 
in the central nervous system (CNS) and causes 
axonal loss [1,2]. Although its etiology is 
unknown, genetic and environmental factors 
are presumed to trigger an autoimmune 
response, resulting in damage to myelin and 
axons [3]. However, inflammation might also 
be neuroprotective or contribute to the repair of 
damaged tissue within the CNS [4]. 
Epicardial fat tissue (EFT), located between the 
myocardium and pericardial visceral layer, 
surrounds the heart. Embryologically, EFT and 
abdominal adipose tissue are of the same origin 
[5]. The levels of lipolysis and lipogenesis in 
EFT are quite high compared to those of other 
adipose tissues [6]. Moreover, EFT is in contact 
with coronary arteries and secretes many 
inflammatory cytokines [5,7]. Studies have 
shown that EFT may be an independent risk 
factor for the presence and severity of 
cardiovascular disease (CVD), probably 
through inflammation or vasoactive pathways 
[8]. 
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Inflammatory cytokines play a crucial role in 
the pathogenesis of MS [9]. MS, which is an 
autoimmune disease, progresses with 
demyelination in the CNS [10]. EFT thickness 
is associated with various autoimmune diseases 
[11,12], and there are various studies showing 
the release of various cytokines from EFT [13]. 
Hence, EFT thickness may be considered a 
significant parameter in MS patients. 
In this study, we aimed to investigate 
echocardiographic EFT thickness, which may 
be an indicator of coronary artery disease, in 
MS patients and compared it with that of 
normal subjects. 
 
Materials and Methods 
The patients who were admitted to a university 
hospital between February 2019 and March 
2020 were included in the study. The study was 
approved by Bolu Abant Izzet Baysal local 
ethics committee (Date: 30/01/2019; Decision 
number: 2019/27). Written and verbal consent 
were obtained from all patients. 
A total of 154 subjects comprising 61 MS 
patients and 93 volunteers matched for gender 
and age were included in our study. The 
demographic characteristics of the participants 
were recorded. The laboratory parameters of 
the patients at the time of admission were 
recorded from the laboratory database. 
Echocardiography (echo) was performed on all 
participants. 
Exclusion criteria 
Patients who had a history of coronary, carotid, 
or peripheral artery atherosclerosis, valvular 
heart disease, heart failure, arrhythmias or 
conduction disorders, prosthetic heart valves, 
pacemaker implantation, significant renal 
failure, severe liver dysfunction, thyroid 
disorders, electrolyte imbalances, systemic 
inflammatory or infectious disease, and poor 
ultrasound image quality were excluded. 
Measurement of epicardial fat thickness 
EFT thickness was measured with a 4-Mhz 
Vivid S6 transducer (GE Vingmed, N-3191, 
Horten, Norway). A blinded cardiologist 
performed the echo under continuous 
electrocardiographic monitoring in the left 
lateral position. Measurements were recorded 
as the average of the values obtained over three 
cardiac cycles. EFT thickness was noted as an 
echo-free or hyperechoic area between the 
epicardium and the visceral layer of the 
pericardium and reflects visceral adipose tissue 
[14]. The assessment of EFT thickness was 
performed from the parasternal long- and short-
axis views of the free wall of the right ventricle. 
The measurement was made at the level of the 
aortic annulus perpendicular to the free wall of 
the right ventricle. The measurements of 
maximum values were made at the end of 
diastole. The intraobserver variation for EFT 
was <5%. 
Statistical analysis 
For all statistical analyses, the 18.0 version of 
SPSS (Statistical Package for the Social 
Sciences) for Windows, (Chicago, Illinois, 
USA) was used. The numerical data were 
expressed as mean ± standard deviation. 
The difference between the study and the 
control groups was evaluated by Student t-test 
for data which were normally distributed. For 
the data which were not normally distributed 
Mann-Whitney’s U-test was used. The 
correlation between EFT and MS was evaluated 
using Spearman's correlation analysis. A p-
value < 0.05 was considered as significant. 
 
Results  
The clinical risk factors and baseline 
characteristics of the patients are shown in 
Table 1. No significant difference was found 
between the groups in terms of baseline 
characteristics (Table 1). 
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Likewise, echocardiographic findings were 
similar in both MS and non-MS groups. 
However, the mean EFT thickness value was 
found significantly higher in MS group than in 
non-MS group (p<0.001) (Table 2). No 




































 groups in terms of laboratory parameters such 
as creatinine, triglyceride, and cholesterol 
values. The Spearman’s correlation test 
revealed that EFT thickness (r=0.33, p<0.001) 
was significantly correlated with the presence 





































Table 1. Baseline characteristics of the study groups. 
 
Baseline characteristics Control Groups (n=93) MS Groups (n=61) P Value 
Age (years) 33±12 36±12 0.25 
Sex (Male/female), n 46/47 22/39 0.08 
SBP (mmHg) 116±14 111±12 0.05 
DBP (mmHg) 71±9 70±7 0.64 
Body mass index (kg/m2) 25±4 25±3 0.17 
Smoking 19 (20%) 17 (28%) 0.27 
Diabetes Mellitus 1 (1%) 3 (5%) 0.14 
Hypertension 2 (2%) 4 (7%) 0.16 
MS: Multiple sclerosis, DBP: Diastolic Blood Pressure, SD: Standard Deviation, SBP: Systolic Blood Pressure.  
 
Table 2. Echocardiographic and laboratory parameters of the study groups. 
 
Variables Control Group (n=93) MS Group (n=61) P Value 
 Mean ± SD  
EF 66±3 65±3 0.36 
LVDD(cm) 4.6±0.4 4.5 ±0.3 0.28 
LVSD(cm) 2.8±0.4 2.8± 0.3 0.26 
PW(cm) 0.86±12 0.88±0.12 0.33 
IVST(cm) 0.88±0.14 0.93±0.14 0.04 
Left atrium 2.9±0.5 3.0±0.4 0.69 
Creatinine (mg/dl) 0.78±12 0.78±11 0.98 
Triglyceride (mg/dl) 107±52 107±59 0.97 
EFT(cm) 0.41±0.17 0.50±0.12 <0.001 
 Median (IQR)  
HDL-cholesterol (mg/dl) 46 (8.8) 51(17.1) 0.07 
LDL-cholesterol (mg/dl) 101(13.7) 102 (38.1) 0.79 
Total cholesterol (mg/dl) 169 (21) 178 (34) 0.08 
EF: Left ventricular ejection fraction, LVDD: Left ventricular end-diastolic diameter, LVSD: Left ventricular end-
systolic diameter, PW: Posterior wall thickness, IVST: Interventriculer septum thickness, EFT: Epicardial fat thickness, 
SD: Standard Deviation, IQR: interquartile range. 
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Figure 1. EFT thickness is significantly higher MS 
group compared to non-MS group. 
 
Discussion 
In the present study it is found that EFT 
thickness was significantly higher in the MS 
group than in the non-MS group, and EFT 
thickness was significantly correlated with MS. 
There is no consensus on whether MS patients 
are at greater risk of CVD when compared to 
the general population [15-18]. While 
Roshanisefat et al. found no difference between 
MS and non-MS patients in terms of CVD 
incidence, Moccia et al. reported that the 
Framingham General Cardiovascular Disease 
Risk Score (FR) was associated with the 
severity, disability, and clinical course of MS 
[19-20]. In some studies, it has been reported 
that indirect markers of CVD, such as high-
sensitive C-reactive protein and carotid intima 
media thickness (CIMT), were related to MS 
[21]. Hence, the overall data suggest an 
increased CVD risk in patients with MS [22]. 
In the context of the reported studies, it is not 
clearly understood whether the increase in 
CVD is related to the presence of obesity, 
hypertension, hyperlipidemia, or diabetes 
mellitus in MS. Further studies are needed to 
solve this issue [22]. An association between 
EFT thickness, CVD, and metabolic syndrome 
has been observed in several studies [8,23]. 
Therefore, our finding of increased EFT 
thickness in MS patients may provide indirect 
evidence and a pathway for the association of 
MS with CVD. 
In the early phase of relapsing-remitting MS, 
demyelination by inflammation predominates, 
while in the progressive phase, neuroaxonal 
damage by neurodegeneration predominates 
[24]. Frischer et al. reported a significant 
association between inflammation and axonal 
injury in MS. In older MS patients with longer 
disease duration, inflammatory infiltrates 
declined to levels similar to those found in age-
matched controls [25]. Therefore, although it is 
not known whether the role of inflammation is 
causative or protective, there is a strong 
association between neurodegeneration and 
inflammation in MS. 
Epicardial fat tissue is a paracrine and 
endocrine tissue and is a source of adiponectin, 
adrenomedullin, anti-inflammatory adipokines, 
and several proinflammatory cytokines, such as 
tumor necrosis factor alpha (TNF-α), 
interleukin (IL)-1, IL-6, and nerve growth 
factor (NGF) [13]. Mazurek et al. [7] examined 
epicardial and subcutaneous adipose tissues 
among elective coronary artery bypass grafting 
surgery patients. Significantly higher mRNA 
and protein levels of IL-1, IL-6, MCP-1, and 
TNF-α were detected in EFT when compared to 
subcutaneous adipose tissue. Coincidentally, 
IL-6, IL-1, and TNF-α levels are associated 
with MS, and these cytokines have been found 
to be related to axonal injury [26]. Additionally, 
Sharief et al. reported that TNF-α levels are 
correlated with MS disease progression and 
disability level [27]. 
The clinical significance of the inflammatory 
potential of EFT and its role in other diseases is 
unclear. Our finding of increased EFT thickness 
among MS patients may provide new insight 
into the association between inflammation and 
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MS. Nevertheless, future studies are needed to 
further explore this aspect. 
There are some limitations not studied. This is 
a single-center study with a small sample size, 
which predisposes it to an inherent selection 
bias. The accuracy and reproducibility of EFT 
thickness measurements with MRI and CT are 
higher than that of echo. Therefore, the use of 
echo for the measurements of EFT thickness 
may reduce the reliability of our results. 
Nonetheless, echo was performed as it is simple 
and inexpensive. Lastly, since EFT has a three-
dimensional distribution, echo, which produces 
a two-dimensional image, may not fully 
evaluate the total amount of epicardial adipose 
tissue. 
Conclusions 
The results of our study suggest that the increase in 
epicardial adipose tissue thickness in MS patients 
may be a predictive factor for cardiovascular 
disease. To our knowledge, this is the first report 
about epicardial adipose tissue in MS patients. 
The clinical significance of this finding and its 
relevance to MS pathogenesis should be 
explored in further studies. 
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